DEA disagrees with firm's meth-resistant claims

by Jim Salter

The Drug Enforcement Administration says a suburban St. Louis pharmaceutical company is wrong for marketing its pseudoephedrine product to imply methamphetamine cannot be made with it.

But Westport Pharmaceuticals insists its Zephrex-D is impractical as an ingredient for meth, even if small amounts of the drug can be extracted from it. The Maryland Heights, Mo., company began selling the cold and allergy medication last year.

The DEA's acting special agent in charge of the St. Louis office, James Shroba, sent Westport a letter dated May 6 and called the company out on its marketing of Zephrex-D as meth-resistant.

Westport spokeswoman Emilie Dolan said Tuesday that only small amounts of meth can be extracted. She says it would cost meth-makers $250 to $500 to make a single dose using Zephrex-D.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

DEA demonstrates how to make meth

May 29, 2007

The Drug Enforcement Administration a held methamphetamine making seminar in Denver to demonstrate what its agents keep off the streets.

Toward a vaccine for methamphetamine abuse

May 11, 2011

Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction — one of the most serious drug abuse problems in the U.S. The report ...

Meds can help recovering meth addicts stay sober

Jun 14, 2012

(Medical Xpress) -- A drug shown to help break alcohol addiction can also help recovering methamphetamine addicts stay clean, a study led by University of Virginia School of Medicine researcher Dr. Bankole A. Johnson has ...

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

Mar 03, 2015

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.